Inhibrx Biosciences Announces Departure of CSO and Appointments of New CSO and President
Inhibrx Biosciences (NASDAQ: INBX) announced key leadership changes as co-founder and CSO Dr. Brendan Eckelman departs to establish a new private biotech company. The company has appointed Dr. Carlos Bais, current Executive VP of Translational Sciences, as the new CSO, and promoted David Matly to President while maintaining his existing roles.
As part of the transition, Inhibrx has entered into an exclusive license agreement with Dr. Eckelman's new venture for certain unused technologies, including provisions for upfront payment and future development milestones. David Matly, who played a important role in Inhibrx's $2.2B asset sale of INBRX-101 to Sanofi in 2024, will oversee clinical development, R&D, technical operations, and regulatory affairs in his expanded role.
Inhibrx Biosciences (NASDAQ: INBX) ha annunciato importanti cambiamenti nel leadership, con la partenza del co-fondatore e CSO Dr. Brendan Eckelman, che lascia per fondare una nuova azienda biotech privata. L'azienda ha nominato Dr. Carlos Bais, attuale VP Esecutivo delle Scienze Traslazionali, come nuovo CSO, e ha promosso David Matly a Presidente, mantenendo i suoi ruoli attuali.
Come parte della transizione, Inhibrx ha stipulato un accordo di licenza esclusiva con la nuova impresa del Dr. Eckelman per alcune tecnologie non utilizzate, inclusi i termini per un pagamento iniziale e traguardi di sviluppo futuri. David Matly, che ha svolto un ruolo importante nella vendita di asset di Inhibrx per $2,2 miliardi di INBRX-101 a Sanofi nel 2024, supervisionerà lo sviluppo clinico, la R&S, le operazioni tecniche e le questioni regolatorie nel suo ruolo ampliato.
Inhibrx Biosciences (NASDAQ: INBX) anunció cambios clave en el liderazgo, ya que el cofundador y CSO Dr. Brendan Eckelman se marcha para establecer una nueva empresa biotecnológica privada. La empresa ha nombrado al Dr. Carlos Bais, actual VP Ejecutivo de Ciencias Traslacionales, como el nuevo CSO, y ha promovido a David Matly a Presidente, manteniendo sus roles existentes.
Como parte de la transición, Inhibrx ha firmado un acuerdo de licencia exclusiva con la nueva empresa del Dr. Eckelman para ciertas tecnologías no utilizadas, incluyendo disposiciones para un pago inicial y hitos de desarrollo futuros. David Matly, quien desempeñó un papel importante en la venta de activos de Inhibrx por $2.2 mil millones de INBRX-101 a Sanofi en 2024, supervisará el desarrollo clínico, I+D, operaciones técnicas y asuntos regulatorios en su rol ampliado.
Inhibrx 바이오사이언스 (NASDAQ: INBX)는 공동 창립자이자 CSO인 브랜든 에켈맨 박사가 새로운 개인 생명공학 회사를 설립하기 위해 떠나면서 주요 리더십 변화를 발표했습니다. 회사는 현재 번역 과학 부사장인 카를로스 바이즈 박사를 새로운 CSO로 임명하고, 데이비드 매틀리를 대통령으로 승진시키면서 기존 역할을 유지했습니다.
전환의 일환으로 Inhibrx는 에켈맨 박사의 새로운 벤처와 특정 미사용 기술에 대한 독점 라이센스 계약을 체결했으며, 여기에는 선불 지급 및 향후 개발 이정표에 대한 조항이 포함됩니다. 2024년 Sanofi에 INBRX-101의 22억 달러 자산 매각에서 중요한 역할을 한 데이비드 매틀리는 확대된 역할에서 임상 개발, 연구 및 개발, 기술 운영 및 규제 업무를 감독할 것입니다.
Inhibrx Biosciences (NASDAQ: INBX) a annoncé des changements clés dans sa direction, le co-fondateur et CSO Dr. Brendan Eckelman quittant l'entreprise pour fonder une nouvelle société biotechnologique privée. L'entreprise a nommé Dr. Carlos Bais, actuel VP Exécutif des Sciences Translationnelles, comme nouveau CSO, et a promu David Matly au poste de Président tout en maintenant ses rôles existants.
Dans le cadre de cette transition, Inhibrx a conclu un accord de licence exclusif avec la nouvelle entreprise du Dr. Eckelman pour certaines technologies inutilisées, y compris des dispositions pour un paiement initial et des jalons de développement futurs. David Matly, qui a joué un rôle important dans la vente d'actifs d'Inhibrx pour 2,2 milliards de dollars d'INBRX-101 à Sanofi en 2024, supervisera le développement clinique, la R&D, les opérations techniques et les affaires réglementaires dans son rôle élargi.
Inhibrx Biosciences (NASDAQ: INBX) gab wichtige Änderungen in der Unternehmensführung bekannt, da der Mitgründer und CSO Dr. Brendan Eckelman das Unternehmen verlässt, um eine neue private Biotech-Firma zu gründen. Das Unternehmen hat Dr. Carlos Bais, derzeitiger Executive VP für Translationale Wissenschaften, zum neuen CSO ernannt und David Matly zum Präsidenten befördert, während er seine bestehenden Rollen beibehält.
Im Rahmen des Übergangs hat Inhibrx einen exklusiven Lizenzvertrag mit Dr. Eckelmans neuem Unternehmen für bestimmte ungenutzte Technologien abgeschlossen, einschließlich Bestimmungen für eine Vorauszahlung und zukünftige Entwicklungsmeilensteine. David Matly, der eine wichtige Rolle beim Verkauf von Inhibrx's Vermögenswerten in Höhe von 2,2 Milliarden Dollar für INBRX-101 an Sanofi im Jahr 2024 gespielt hat, wird in seiner erweiterten Rolle die klinische Entwicklung, F&E, technische Abläufe und regulatorische Angelegenheiten überwachen.
- Recent successful $2.2B asset sale of INBRX-101 to Sanofi demonstrates strong business execution
- Licensing agreement for unused technologies creates potential future milestone revenue
- Internal promotion of experienced executives ensures continuity in leadership
- Departure of co-founder and CSO could impact company's scientific leadership
- Two programs only in clinical-stage development indicates pipeline
Dr. Eckelman leaves the Company to establish a newly-formed private biotechnology company, where he will be founder and Chief Executive Officer. Inhibrx and the new company have entered into an exclusive license agreement for the rights to certain technologies no longer being pursued by Inhibrx. The agreement includes an upfront payment upon completion of the initial funding of Dr. Eckelman's new company and other future development milestones.
"I would like to express my deep gratitude to Brendan for his extraordinary contributions to Inhibrx over the last 15 years," said Mark Lappe, CEO of Inhibrx. "Brendan has had a profound impact on Inhibrx and we expect he will lead this next endeavor to the same success."
"I am immensely proud of the achievements and groundbreaking innovations we have developed since co-founding Inhibrx in 2010. As I announce my departure, it is a bittersweet moment.," says Dr. Eckelman. "I have the utmost confidence in the team and the culture of innovation I'm leaving behind and look forward to continuing to support Inhibrx in my capacity as a shareholder."
Dr. Carlos Bais, the Company's current Executive Vice President of Translational Sciences, will be appointed to CSO following Dr. Eckelman's departure.
Additionally, the Company also announced the promotion of David Matly to President in addition to his existing roles as Chief Commercial and Business Development Officer. In David's new role as President, he will continue to lead the commercial and business development functions as well as oversee clinical development and operations, R&D, technical operations and regulatory affairs. Notably, David played a key leadership role in Inhibrx, Inc.'s asset sale of INBRX-101 to Sanofi for up to
"We believe we are exceptionally well-positioned for continued success as Carlos steps into the role of CSO and David into the role of President," continued Mr. Lappe. "Carlos's strong scientific background and expertise in late-stage development make him a perfect candidate to assume the CSO role. And David's cross-functional understanding of successfully delivering best-in-class new therapies, combined with his ambition and commitment to the Company will prove to be pivotal to our future success. Each will play a crucial role as we continue to execute on our clinical programs in an effort to deliver significant impact to patients while maximizing the value to our shareholders."
About Dr. Bais
Dr. Bais began his career in the biopharmaceutical industry as a research lab head at Genentech and then as a Senior Director and Principal Scientist in the oncology biomarker development department. Later he served as a Director of Translational Medicine for cancer immunotherapy at Medimmune/Astrazeneca, and most recently prior to Inhibrx, as a Senior Director and Principal Scientist in the oncology biomarker development department at Genentech/Roche. Throughout his career, Dr. Bais led impactful research and translational strategies for multiple late-stage programs that resulted in high impact publications and drug approvals in diagnostic-positive patient subpopulations. Some of the drugs Dr. Bais and his team supported included Astrazeneca's Durvalumab (anti-PD-L1) and Tremelimumab (anti-CTLA-4), and Roche's Atezoluzimab (anti-PD-L1), Tiragolumab (anti-Tigit), and Bevacizumab (Avastin, anti-VEGF); he also oversaw biomarker support for early-stage drug candidate development, including T-cell engagers and therapies, along with individualized neoantigen cancer vaccines.
About Mr. Matly
Mr. Matly joined Inhibrx, Inc. in October 2021 from Novartis, where he most recently served as the global Vice President of the MDS/AML franchise. In this role, he was responsible for the launch preparation of their flagship program and building the MDS/AML portfolio, including the evaluation of in-licensing and M&A opportunities. Prior to this role, Mr. Matly was Novartis Oncology's global commercial lead of the sickle cell disease therapeutic area, leading the launch of ADAKVEO, and also serving as the global commercial lead of PROMACTA/REVOLADE. Prior to Novartis, Mr. Matly was the VP of Business Development at Chrono Therapeutics, a private venture capital-backed company. Mr. Matly began his career at Eli Lilly, holding several positions of increasing responsibility in sales and marketing, most notably leading the US launch of CYRAMZA in metastatic lung cancer.
About Inhibrx Biosciences, Inc.
Inhibrx Biosciences is a clinical-stage biopharmaceutical company focused on developing a broad pipeline of novel biologic therapeutic candidates. Inhibrx Biosciences utilizes diverse methods of protein engineering to address the specific requirements of complex target and disease biology, including its proprietary protein engineering platforms. Inhibrx Biosciences was incorporated in January 2024 as a direct, wholly-owned subsidiary of Inhibrx, Inc. Prior to the sale of Inhibrx, Inc. and the INBRX-101 program to Sanofi S.A., Inhibrx Biosciences acquired certain corporate infrastructure and other assets and liabilities through a series of internal restructuring transactions effected by Inhibrx, Inc. Inhibrx, Inc. also completed a distribution to holders of its shares of common stock of
Forward-Looking Statements
Inhibrx cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements. These statements are based on Inhibrx's current beliefs and expectations. These forward-looking statements include, but are not limited to, statements regarding: the future success of the Company, future clinical development of Inhibrx's therapeutic candidates and which technologies it may pursue, including statements regarding the timing of future data readouts, and evaluations and judgments regarding Inhibrx's position and success. Actual results may differ from those set forth in this press release due to the risks and uncertainties inherent in Inhibrx's business, including, without limitation, risks and uncertainties regarding: the initiation, timing, progress and results of its preclinical studies and clinical trials, and its research and development programs; its ability to advance therapeutic candidates into, and successfully complete, clinical trials; its interpretation of initial, interim or preliminary data from its clinical trials, including interpretations regarding disease control and disease response; the timing or likelihood of regulatory filings and approvals; any adverse impacts from the transition in senior leadership roles; the successful commercialization of its therapeutic candidates, if approved; the pricing, coverage and reimbursement of its therapeutic candidates, if approved; its ability to utilize its technology platform to generate and advance additional therapeutic candidates; the implementation of its business model and strategic plans for its business and therapeutic candidates; its ability to successfully manufacture therapeutic candidates for clinical trials and commercial use, if approved; its ability to contract with third-party suppliers and manufacturers and their ability to perform adequately; the scope of protection it is able to establish and maintain for intellectual property rights covering its therapeutic candidates; its ability to enter into strategic partnerships and the potential benefits of these partnerships; its estimates regarding expenses, capital requirements and needs for additional financing and financial performance; its ability to raise funds needed to satisfy its capital requirements, which may depend on financial, economic and market conditions and other factors, over which it may have no or limited control; developments relating to its competitors and industry; and other risks described from time to time in the "Risk Factors" section of its filings with the
Investor and Media Contact:
Kelly Deck, CFO
ir@inhibrx.com
858-795-4260
View original content to download multimedia:https://www.prnewswire.com/news-releases/inhibrx-biosciences-announces-departure-of-cso-and-appointments-of-new-cso-and-president-302416729.html
SOURCE Inhibrx Biosciences, Inc.
FAQ
What leadership changes were announced at Inhibrx (INBX) in April 2025?
What is the licensing agreement between INBX and Dr. Eckelman's new company?
What was David Matly's role in INBX's recent major transaction?
What will be David Matly's responsibilities as the new President of INBX?
